Get started
Author

Tanner Hardy

Observed names: R. Tanner Hardy, Richard Hardy, Richard Tanner Hardy, T.T. Hardy
ORCID: 0000-0002-2969-0944
Observed ORCID: 0000-0002-2969-0944
OpenAlex ID: A5027657452
Terahertz waveform considerations for nonlinearly driving lattice vibrations
2019 · Brittany E. Knighton, R. Tanner Hardy, et al. · Journal of Applied Physics · 54
HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2022 · Yuanqing Ma, Allison Joyce, et al. · Clinical Cancer Research · 18
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States
2026 · Chadi Hage Chehade, Zeynep Irem Ozay, et al. · JAMA Network Open · 6
PDF
Rates of first next-generation sequencing (NGS) testing at the end of life in patients (pts) with advanced urothelial carcinoma (aUC).
2025 · Chadi Hage Chehade, Yeonjung Jo, et al. · Journal of Clinical Oncology · 1
PDF
Two-dimensional THz Spectroscopy of Multiferroic BiFeO3
2020 · Brittany E. Knighton, Megan F. Nielson, et al. · International Conference on Infrared, Millimeter, and Terahertz Waves (IRMMW-THz) · 1
Real-world use and effectiveness of first-line enfortumab vedotin (EV) with pembrolizumab (P) in patients with advanced urothelial carcinoma (aUC).
2026 · Zeynep Irem Ozay, Yeonjung Jo, et al. · Journal of Clinical Oncology
PDF
Treatment (Rx) patterns and survival outcomes in patients with metastatic chromophobe renal cell carcinoma (mchRCC).
2026 · Richard Tanner Hardy, Yeonjung Jo, et al. · Journal of Clinical Oncology
PDF
End-of-life treatment patterns in patients (pts) with metastatic renal cell carcinoma (mRCC).
2026 · Ayana Srivastava, Yeonjung Jo, et al. · Journal of Clinical Oncology
PDF
Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Supplementary Data Legend LS1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Table S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Table S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025 · Yuanqing Ma, Allison Joyce, et al.
2637P Survival outcomes based on the number of cycles of Ipilimumab in patients (pts) in the US with metastatic clear cell renal cell carcinoma (mccRCC) treated with first-line (1L) Ipilimumab (Ipi) plus Nivolumab (Nivo)
2025 · T.T. Hardy, Y. Jo, et al. · Annals of Oncology
Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2023 · Yuanqing Ma, Allison Joyce, et al.
Table S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2023 · Yuanqing Ma, Allison Joyce, et al.
Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2023 · Yuanqing Ma, Allison Joyce, et al.
Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2023 · Yuanqing Ma, Allison Joyce, et al.
Table S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2023 · Yuanqing Ma, Allison Joyce, et al.
Works count: 49
Citation count: 80
H-index: 3
I10-index: 2
Year
Topic
Type